Integral Health Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Integral Health Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-125,000	Closed	-$4.19M	–	83
2025 Q1	$4.19M	Sell	125,000 -175,000	-58%	-$6.54M	0.45%	58
2024 Q4	$15.3M	Hold	300,000	–	–	1.31%	27
2024 Q3	$15.3M	Sell	300,000 -100,000	-25%	-$5.16M	1.72%	18
2024 Q2	$17.9M	Buy	400,000 +75,000	+23%	+$3.46M	1.7%	16
2024 Q1	$15.2M	Buy	325,000 +125,000	+63%	+$4.89M	1.41%	27
2023 Q4	$7.12M	Hold	200,000	–	–	0.97%	47
2023 Q3	$5.95M	Buy	+200,000	New	+$4.12M	0.82%	47

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Integral Health Asset Management's CRNX Position: Q2 2025 in Review

Integral Health Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 125,000 shares — an estimated $4.19M sold.

Integral Health Asset Management first reported a position in CRNX in Q3 2023 and held it in 7 quarters. The position peaked at $17.9M in Q2 2024. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

Integral Health Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Integral Health Asset Management sold 125,000 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $4.19M.
Integral Health Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2023 and held it in 7 quarters.
Integral Health Asset Management's Crinetics Pharmaceuticals position peaked at $17.9M in Q2 2024.
222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Integral Health Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.